Morfitt came to Eden Prairie–based CNS, whose flagship product is the Breathe-Right nasal strip, in 1998 and turned the company around. When she arrived, CNS was losing sales and its stock price (Nasdaq: CNXS) was headed down from more than $23 in 1996 to just above $3 in 1999. Repositioning the product and building sales took time. But with annual sales around $119 million and the share price above $29, Morfitt and the CNS board announced in October that GlaxoSmithKline would buy the company for $37.50 per share in cash—giving shareholders a 31 percent premium. Now we wonder: Will Morfitt stay or go? And if she goes, what local company might lure her considerable talents to its top spot?